ocular surface change after switching from others prostaglandins to tafluprost and preservative free tafluprost in glaucoma

Ocular surface change after switching from others prostaglandins to Tafluprost and Preservative-free Tafluprost in glaucoma.

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

TCTR

Registry ID

TCTR20170420001

Enrollment

Registered

2017-04-20

Start date

2017-01-28

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy patient

Interventions

left eye use non preservative tafluprost right eye sue preservative tafluprost ,left eye use preservative tafluprost right eye use non preservative tafluprost

Treatment,Treatment

group 1,group 2

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: open angle glaucoma both eyes C:D ratio 6/60 on anti glaucoma drug(prostaglandins group) > 6 months diagnosis of ocular surface disease both eyes no other drug used no history of eye trauma

Exclusion criteria

Exclusion criteria: history of uveitis or eyelid disease systemic or topical steroid use in 6 months contact lens used

Design outcomes

Primary

Measure	Time frame
ocular surface change 6 months prospective cohort study	—

Secondary

Measure	Time frame
intraocular pressure control 6 months tension applanation	—

Contacts

Public Contactkarnthida choojun

medical school

karnthida034@gmail.com0891144397

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026